Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue
−2.20%
EPS
+530.3%
Free cash flow
+16.3%
Total debt
+11.8%

Quarter to September 2026, against a year earlier

313.98 12.31 −3.77%
Market cap
$14.9B
P/E
300×
Fwd P/E
89.2×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a

Charles River Laboratories International, Inc. (CRL) Net income

Alert me on Net income

Charles River Laboratories International, Inc.'s net income for fiscal 2025 was −$142.2M, compared with $25.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was $42.6M. Over the past ten years it has ranged from −$142.2M (fiscal 2025) to $492.6M (fiscal 2022) — the current reading is the lowest in ten years. Net income has fallen for 3 consecutive fiscal years. Charles River Laboratories International, Inc. ranks 19th of 49 Diagnostics & Research companies by net income.

Net income, annual

Embed this chart

Annual newest first

Period Net income Change
FY2025 −$142.2M —
FY2024 $25.3M (94.74%)
FY2023 $480.4M (2.48%)
FY2022 $492.6M 23.51%
FY2021 $398.8M 9.18%
FY2020 $365.3M 43.79%
FY2019 $254.1M 11.08%
FY2018 $228.7M 82.32%
FY2017 $125.4M (19.77%)
FY2016 $156.4M 3.49%

Quarterly newest first

Period Net income Change
Sep 2026 $334.4M —
Jun 2026 −$760.0K —
Mar 2026 −$14.8M —
Dec 2025 −$276.3M —
43 more quarters

Against its own ten years

Low −$142.2M High $492.6M
Ten-year median $228.7M
Current reading's percentile 9

Net income against peers

What Net income is

Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.

Reported line item

The full definition of Net income →

More on CRL